Top 10 tscan.com Competitors

calliditas.se

See how we pioneered the first treatment specifically designed for IgA nephropathy.

adaptimmune.com

Adaptimmune is revolutionizing cancer therapy by developing TCR T-cell therapies (called SPEAR T-cells). Find out how more about these treatments.

karmanos.org

the barbara ann karmanos cancer institute is one of 57 cancer centers designated as a comprehensive cancer center by the national cancer institute. our team has access to more than 250 promising new cancer-specific treatments found only at karmanos. cancer treatment in michigan and ohio.

onclive.com

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

iobiotech.com

We are developing product candidates that leverage our T-win® platform to generate immune-modulatory, off-the-shelf therapeutic cancer vaccines designed to kill both tumor cells and immune-suppressive cells in the TME and improve tumor cell killing in multiple cancer indications.

isa-pharma.com

The combination of ISA101b and cemiplimab in these patients resulted in an overall response rate (ORR) of 15.4%, as per investigator assessment. Long term (≥6 months) disease stabilization was achieved in 26.9% of all patients. The combination of cemiplimab and ISA101b was generally well tolerated with a safety profile resembling that of anti-PD-1 monotherapy. There were two grade 3 adverse events related to ISA101b. Grade 4-5 events related to study treatment did not occur. Re-ignition of an anti-tumor effect of anti-PD-1 therapy after failure of checkpoint inhibition by the addition of a therapeutic vaccine is a unique feature.